

# Imugene Ltd

20:57 03 Jun 2019

## Imugene presents new HER-Vaxx cancer vaccine results

Imugene Ltd (ASX:IMU) has received positive data from the ongoing patients in the phase Ib study of its HER-Vaxx cancer vaccine.

The study completed enrolment in 2018 and is ongoing, patients receive HER-Vaxx every three months to maintain high levels of cancer-targeting antibodies.

A phase II study was initiated in March 2019 dosing patients at the highest phase Ib dose.

The presentation given at the ASCO annual meeting in Chicago showed that by day 182 of the trial, patients dosed with the highest dose of HER-Vaxx tumours had either shrunk further or stabilised.

In one patient, their tumour has shrunk more than 70% since joining the trial.

We've just released news on our positive new 6-month data: our HER-Vaxx-chemo combination shrinks or stabilises tumour growth | Read the ASX announcement here ><https://t.co/pZ5q439xSQ> #MedTech #Pharma #ASCO19 (ASX: IMU) [pic.twitter.com/o2IDThBVZY](https://twitter.com/o2IDThBVZY)

— Imugene | Cancer Immunotherapies (@TeamImugene) June 3, 2019

All patients on the highest dose have received their day-266 does and these results will be presented in Barcelona on 3-6 July 2019.

Imugene's managing director and CEO Leslie Chong said: "There is continued interest in the positive data from our phase Ib trial which supports our B-cell platform cancer vaccine strategy for treating HER-2 positive gastric cancer."

READ: Imugene appoints venture capital executive to board

Last month, Imugene appointed Dr Jens Eckstein as a non-executive director to its board.

Dr Eckstein is a leading biotechnology executive and managing partner of Apollo Ventures, a venture capital firm that invests in seed and early stage biotechnology companies.

He has more than 15 years venture capital experience funding early to clinical stage biopharmaceutical companies.

Strong pipeline of cancer vaccines in development

**Price:** 0.057

**Market Cap:** \$206.05 m

### 1 Year Share Price Graph



### Share Information

**Code:** IMU

**Listing:** ASX

**52 week High Low**  
0.063 0.013

**Sector:** Pharma & Biotech

**Website:** [www.imugene.com](http://www.imugene.com)

### Company Synopsis:

Imugene Ltd (ASX:IMU) is listed on the Australian Securities Exchange.

action@proactiveinvestors.com

The company has a strong pipeline of cancer vaccines in development.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Imugene Ltd named herein, including the promotion by the Company of Imugene Ltd in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand (\$25,000).